Experimental cancer pill targets Hard-to-Treat gene mutations
NCT ID NCT06270082
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IK-595 (oral tablet)
What this could lead to
If successful, this could point toward a new treatment option for patients with certain gene-altered advanced solid tumors.
What could go wrong
This was a very early (Phase 1) study that was terminated, so results are limited. The drug may not prove safe or effective in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
INOVA Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center
Washington D.C., District of Columbia, 20016, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Next Oncology
Austin, Texas, 78758, United States
-
Next Oncology- San Antonio
San Antonio, Texas, 78229, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthOne
Denver, Colorado, 80218, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pittsburgh Medical Center- Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States